Background: Maintenance therapy with full-dose erlotinib for patients with advanced non-
small cell lung cancer (NSCLC) has demonstrated a significant overall survival (OS) benefit …

7022 Background: A previous CALGB trial suggested a benefit for carboplatin-paclitaxel
(CP) over P alone in pts with PS 2. Erlotinib (E) has activity in previously treated pts with low …

Background. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy
is clearly beneficial in patients with advanced EGFR-mutated non-small cell lung cancer …

Introduction. The aim of this retrospective study was to examine effect of erlotinib in patients
with advanced non‐small cell lung cancer (NSCLC) in second‐line and further therapy in …

Background: Two new agents have recently been licensed as maintenance therapy for
advanced non-small-cell lung cancer (NSCLC) by the US Food and Drug Administration …

Abstract Objective The phase III IUNO trial assessed the benefit of maintenance erlotinib
versus erlotinib at progression in advanced/metastatic non-small-cell lung cancer (NSCLC) …

Introduction Pemetrexed and erlotinib have been approved as second-line monotherapy for
locally advanced or metastatic non-small cell lung cancer (NSCLC). This multicentre …

Aims: The efficacy of erlotinib (Tarceva, Roche Products, Dee Why, Australia) has been
demonstrated in patients with advanced non‐small‐cell lung cancer (NSCLC). Tarceva lung …

Purpose To investigate the efficacy of erlotinib versus docetaxel in previously treated
patients with advanced non–small-cell lung cancer (NSCLC) in an epidermal growth factor …

e19103 Background: The standards in 2nd-line therapy with advanced non-small cell lung
cancer (NSCLC) were erlotinib or pemetrexed as well as docetaxel. To evaluate the …